Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04634435 · ClinicalTrials.gov registry record · Phase 1
Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients
A Phase 1 study, sponsored by Biohaven Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT04634435: Completed Phase 1 study, sponsored by Biohaven Pharmaceuticals.
NCT04634435 is a Phase 1 study that has completed, run by Biohaven Pharmaceuticals. The registered enrollment target is 7 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04634435, a Phase 1 study, has completed, sponsored by Biohaven Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is an open-label single center Phase 1a/1b study with the primary objective of establishing the safety and exploring the efficacy of infusing the ex vivo combination product of BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2 in the peri-transplant setting in MM patients with minimal residual disease (MRD+) in first or second remission.
Interventions
- COMBINATION_PRODUCT BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2021-10-21 |
| Est. Completion | 2025-01-10 |
| Phase | Phase 1 |
What the finished NCT04634435 record still lists
NCT04634435 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 1 intervention - of which BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2 is the first listed.
NCT04634435 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04634435 about?
NCT04634435 is a clinical study titled "Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients". This is an open-label single center Phase 1a/1b study with the primary objective of establishing the safety and exploring the efficacy of infusing the ex vivo combination product of BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2 in the peri-transplant setting ...
What is the current status of trial NCT04634435?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2021-10-21. Estimated completion is 2025-01-10.
What interventions are being tested in trial NCT04634435?
The interventions under investigation include: BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2 (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04634435?
This trial is sponsored by Biohaven Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04634435's enrollment target sits among peer trials
7 1972nd of 2000 higher than 27 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI